Katja Rohwedder heads the medical strategy for Finerenone in the Global Medical Affairs team, based in Berlin, Germany.

She is a MD and joined Bayer in 2022 in her current role. She has extensive experience from working in the pharma industry for more than 20 years. Before, she worked in different global and local roles in AstraZeneca, including the clinical development of dapagliflozin.